AN ANALYSIS OF COMPILATION OF THE RESTRICTIVE INVENTORIES IN THE RUSSIAN FEDERATION AS EXEMPLIFIED WITH «VITALLY ESSENTIAL AND INDISPENSABLE DRUGS» (VEID): THE ROLE OF PHARMACOECONOMICS

Background. In 2014, the first experiment of drug inclusion into or exclusion from restrictive inventories based on a score system and independent expert assessments has been carried out. Based on data obtained in 2014, the present authors have developed and tested linear mathematical models for making decisions concerning drug inclusion into restrictive inventories. The objective of the present work was to develop a model for the year 2016 with account of novel and supplementary data derived from the analysis of such inventories. Materials and methods. The linear models that have been developed and adopted earlier were used. The analysis included 141 records of medicinal drugs. Analyzed were verdicts provided by expert institutions and by chief non-stuff experts and the final decisions made by Interdisciplinary Panel. Results. In 2016, the Restrictive Inventory of VEID included 43 drugs. It was shown that the model for making decisions by expert organizations was associated with a 7,09% error (12,4% in 2014). The model for chief on-stuff experts was associated with a 7% error (10% in 2014). The above positive changes suggest that persons involved are able to become trained in using the formal approaches. The model for making the final decision by interdisciplinary panel was associated with a 42% error vs. 35% found earlier. Conclusion. Linear models are effective instruments for making prognoses concerning the inclusion of medicinal drugs into restrictive inventories. However, the currently adopted system should be formalized further.

restrictive inventory, medicinal drugs, linear models, formalized approach, ограничительный перечень, лекарственные средства, линейные модели, формализованный подход

1. http://www.consultant.ru/document/cons_doc_LAW_167999/ 5.1.2016.

2. http://government.ru/media/files/u8akRanvTl4.pdf 5.1.2016.

3. Прасолов А.В., Колбин А.С., Максимкина Е.А., Голант З.М., Полушин Ю.С., Курылев А.А., Вилюм И.А., Балыкина Ю.Е. Моделирование включения лекарственных средств в ограничительные перечни (пример - ЖНВЛП). Анализ данных 2014 года // Ремедиум.- № 4.- 2015.- С. 58-63.

4. http://publication.pravo.gov.ru/Document/View/0001201601040062 5.1.2016.

5. Власов В.В., Плавинский С.Л. Варианты лекарственного обеспечения для России: уроки стран Европы и всего мира.- М.: Медиасфера, 2013.- 107 с.